JP2016128513A5 - - Google Patents

Download PDF

Info

Publication number
JP2016128513A5
JP2016128513A5 JP2016068623A JP2016068623A JP2016128513A5 JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5 JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5
Authority
JP
Japan
Prior art keywords
seq
positions
use according
hbv
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016068623A
Other languages
English (en)
Japanese (ja)
Other versions
JP6109989B2 (ja
JP2016128513A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016128513A publication Critical patent/JP2016128513A/ja
Publication of JP2016128513A5 publication Critical patent/JP2016128513A5/ja
Application granted granted Critical
Publication of JP6109989B2 publication Critical patent/JP6109989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016068623A 2011-02-12 2016-03-30 慢性b型肝炎感染症のための酵母系治療薬 Active JP6109989B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161442204P 2011-02-12 2011-02-12
US61/442,204 2011-02-12
US201161496945P 2011-06-14 2011-06-14
US61/496,945 2011-06-14
US201161507361P 2011-07-13 2011-07-13
US61/507,361 2011-07-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015025534A Division JP5911983B2 (ja) 2011-02-12 2015-02-12 慢性b型肝炎感染症のための酵母系治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017043689A Division JP2017105834A (ja) 2011-02-12 2017-03-08 慢性b型肝炎感染症のための酵母系治療薬

Publications (3)

Publication Number Publication Date
JP2016128513A JP2016128513A (ja) 2016-07-14
JP2016128513A5 true JP2016128513A5 (cg-RX-API-DMAC7.html) 2016-12-22
JP6109989B2 JP6109989B2 (ja) 2017-04-05

Family

ID=46638950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013553534A Active JP5745102B2 (ja) 2011-02-12 2012-02-09 慢性b型肝炎感染症のための酵母系免疫療法組成物
JP2015025534A Active JP5911983B2 (ja) 2011-02-12 2015-02-12 慢性b型肝炎感染症のための酵母系治療薬
JP2016068623A Active JP6109989B2 (ja) 2011-02-12 2016-03-30 慢性b型肝炎感染症のための酵母系治療薬
JP2017043689A Pending JP2017105834A (ja) 2011-02-12 2017-03-08 慢性b型肝炎感染症のための酵母系治療薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013553534A Active JP5745102B2 (ja) 2011-02-12 2012-02-09 慢性b型肝炎感染症のための酵母系免疫療法組成物
JP2015025534A Active JP5911983B2 (ja) 2011-02-12 2015-02-12 慢性b型肝炎感染症のための酵母系治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017043689A Pending JP2017105834A (ja) 2011-02-12 2017-03-08 慢性b型肝炎感染症のための酵母系治療薬

Country Status (25)

Country Link
US (7) US8877205B2 (cg-RX-API-DMAC7.html)
EP (2) EP2672991B1 (cg-RX-API-DMAC7.html)
JP (4) JP5745102B2 (cg-RX-API-DMAC7.html)
KR (1) KR102026840B1 (cg-RX-API-DMAC7.html)
CN (1) CN103476426B (cg-RX-API-DMAC7.html)
AP (1) AP2013007110A0 (cg-RX-API-DMAC7.html)
AU (2) AU2012214394B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013020425A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827150C (cg-RX-API-DMAC7.html)
CL (1) CL2013002334A1 (cg-RX-API-DMAC7.html)
CO (1) CO6791572A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130424A (cg-RX-API-DMAC7.html)
EA (1) EA028659B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012862A (cg-RX-API-DMAC7.html)
ES (1) ES2643389T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248120A1 (cg-RX-API-DMAC7.html)
IL (1) IL227900B (cg-RX-API-DMAC7.html)
MA (1) MA34956B1 (cg-RX-API-DMAC7.html)
PE (1) PE20140844A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501683A1 (cg-RX-API-DMAC7.html)
SG (1) SG192285A1 (cg-RX-API-DMAC7.html)
TW (1) TWI504608B (cg-RX-API-DMAC7.html)
UA (1) UA112859C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012109404A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306481B (cg-RX-API-DMAC7.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA037377B1 (ru) 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
CN103476426B (zh) 2011-02-12 2021-08-10 全球免疫股份有限公司 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
BR112014003477B1 (pt) 2011-08-17 2021-11-03 Globeimmune, Inc. Composição imunoterapêutica de muc1 de levedura
AU2013281221B2 (en) 2012-06-26 2018-05-17 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014072524A1 (en) 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI728239B (zh) 2013-03-26 2021-05-21 美商環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
WO2015157639A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
WO2016085284A1 (ko) * 2014-11-28 2016-06-02 (주)셀트리온 B형 간염 바이러스 표면 항원의 에피토프 및 이에 특이적으로 결합하는 b형 간염 바이러스 중화 결합 분자
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
PH12021551982A1 (en) 2015-03-04 2022-09-05 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン,インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
SG11201803474UA (en) * 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CA3002508A1 (en) * 2016-01-12 2017-07-20 Ulrike Protzer Means and methods for treating hbv
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN106421774B (zh) * 2016-09-08 2019-05-28 中国科学院生物物理研究所 PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途
PE20191353A1 (es) 2016-10-14 2019-10-01 Prec Biosciences Inc Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN110612118B (zh) * 2017-06-05 2024-02-13 比科尔公司 用于引起针对hbv的免疫应答的病毒样粒子
WO2019040102A1 (en) 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
JP7317017B2 (ja) * 2017-12-19 2023-07-28 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー B型肝炎ウイルス(hbv)ワクチンおよびその使用
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
WO2019126120A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
AU2019231652B2 (en) * 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
KR102651420B1 (ko) 2018-07-06 2024-03-28 길리애드 사이언시즈, 인코포레이티드 치료 헤테로시클릭 화합물
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
AU2020231201B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020254876A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
UA129329C2 (uk) 2019-06-25 2025-03-19 Гіліад Сайєнсіз, Інк. ЗЛИТІ БІЛКИ FLT3L-Fc
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
MX2022002270A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.
WO2021060450A1 (ja) * 2019-09-27 2021-04-01 富士レビオ株式会社 B型肝炎ウイルスコア関連抗原のイムノアッセイ及びそのためのキット
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
EP4087605A1 (en) * 2020-01-09 2022-11-16 Virion Therapeutics, LLC Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4171594A4 (en) * 2020-06-29 2024-08-07 The Trustees Of Columbia University In The City Of New York YEAST-BASED VACCINES
CN116194144A (zh) 2020-08-07 2023-05-30 吉利德科学公司 膦酰胺核苷酸类似物的前药及其药物用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
WO2024220982A1 (en) * 2023-04-21 2024-10-24 The Wistar Institute Of Anatomy And Biology Compositions comprising aptamers and methods of modulating the immune response using the same
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5164485A (en) * 1985-08-20 1992-11-17 Takeda Chemical Industries, Ltd. Modified hepatitis B virus surface antigen P31 and production thereof
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
WO1994012617A1 (en) * 1992-11-25 1994-06-09 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
JP3713900B2 (ja) 1996-07-19 2005-11-09 ソニー株式会社 負極材料及びこれを用いた非水電解液二次電池
CA2320488C (en) * 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
HK1048492A1 (zh) * 1999-12-03 2003-04-04 Innogenetics N.V. 新的hbv序列
GB0216074D0 (en) * 2002-07-11 2002-08-21 Weatherford Lamb Improving collapse resistance of tubing
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
JP2004527450A (ja) 2000-04-06 2004-09-09 シーア ファーマスーティカルズ エルエルシー 微生物送達システム
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
CN1171636C (zh) * 2001-06-06 2004-10-20 中国人民解放军第二军医大学 一种乙型肝炎dna疫苗
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
DE10339927A1 (de) 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP1988919A4 (en) 2006-02-02 2009-06-10 Globeimmune Inc VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE
MX2008012392A (es) 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
EP2121013B1 (en) 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
CN101036784B (zh) * 2007-03-09 2010-11-10 中国人民解放军第二军医大学 一种乙型肝炎治疗性细胞毒性t细胞表位疫苗及其制备方法
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) * 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN103476426B (zh) * 2011-02-12 2021-08-10 全球免疫股份有限公司 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
BR112014003477B1 (pt) 2011-08-17 2021-11-03 Globeimmune, Inc. Composição imunoterapêutica de muc1 de levedura

Similar Documents

Publication Publication Date Title
JP2016128513A5 (cg-RX-API-DMAC7.html)
JP2015096557A5 (cg-RX-API-DMAC7.html)
Spyrou et al. Hepatitis B: current status of therapy and future therapies
Kim et al. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Liang et al. Present and future therapies of hepatitis B: from discovery to cure
Shouval et al. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine
Paladini et al. The worldwide impact of vaccination on the control and protection of viral hepatitis B
TWI575070B (zh) Hbv聚合酶突變體
CN110612118B (zh) 用于引起针对hbv的免疫应答的病毒样粒子
Li et al. Research progress of therapeutic vaccines for treating chronic hepatitis B
JP2014507144A5 (ja) 慢性b型肝炎感染症のための酵母系免疫療法組成物
JP2014527404A5 (cg-RX-API-DMAC7.html)
TWI732156B (zh) 用於治療和/或預防與肝炎病毒相關的疾病或病症的雙二氮雜雙環化合物
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
JP2017515508A5 (cg-RX-API-DMAC7.html)
Yoshida et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study
Karimkhanilouyi et al. Nucleic acid vaccines for hepatitis B and C virus
Jilg Novel hepatitis B vaccines
Tang et al. Advances in new antivirals for chronic hepatitis B
JP2017522326A5 (cg-RX-API-DMAC7.html)
EP3437654B1 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
Pentón-Arias et al. Cuban prophylactic and therapeutic vaccines for controlling hepatitis B
CN101717433A (zh) 一种多肽免疫原及其制备方法和应用
JP2014534262A5 (cg-RX-API-DMAC7.html)
CN106421774A (zh) PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途